Canakinumab in Patients With COVID-19 and Type 2 Diabetes : Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial
Patients with a metabolic syndrome (overweight, diabetes, hypertension) have a particularly bad outcome if infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). This may be explained by an over-activation of the Interleukin-1 (IL-1) beta system. Metabolic stress (increased glucose and lipid levels) induces NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) -mediated IL-1beta secretion. SARS-CoV2 also activates NLRP3. Therefore, the study proposes that metabolic stress in patients with overweight and diabetes potentiates COVID-19 induced hyperinflammatory syndrome leading to excess mortality in these vulnerable patients. Canakinumab (Ilaris®) is a recombinant, human monoclonal antibody antagonizing IL-1beta by blocking IL-1beta activity. The aim of the study is to investigate the effect of canakinumab in type 2 diabetic patients with COVID-19..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
ClinicalTrials.gov - (2021) vom: 08. Sept. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: August 12, 2020, Last downloaded: ClinicalTrials.gov processed this data on September 13, 2021, Last updated: September 15, 2021 |
---|
Study ID: |
NCT04510493 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003485633 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003485633 | ||
003 | DE-627 | ||
005 | 20230425192925.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003485633 | ||
035 | |a (UBBS_Klinische_Studien)NCT04510493 | ||
035 | |a (UBBS_Klinische_Studien)2020-02008; me20Donath2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Canakinumab in Patients With COVID-19 and Type 2 Diabetes |b Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: August 12, 2020, Last downloaded: ClinicalTrials.gov processed this data on September 13, 2021, Last updated: September 15, 2021 | ||
520 | |a Patients with a metabolic syndrome (overweight, diabetes, hypertension) have a particularly bad outcome if infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). This may be explained by an over-activation of the Interleukin-1 (IL-1) beta system. Metabolic stress (increased glucose and lipid levels) induces NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) -mediated IL-1beta secretion. SARS-CoV2 also activates NLRP3. Therefore, the study proposes that metabolic stress in patients with overweight and diabetes potentiates COVID-19 induced hyperinflammatory syndrome leading to excess mortality in these vulnerable patients. Canakinumab (Ilaris®) is a recombinant, human monoclonal antibody antagonizing IL-1beta by blocking IL-1beta activity. The aim of the study is to investigate the effect of canakinumab in type 2 diabetic patients with COVID-19. | ||
650 | 2 | |a Coronavirus Infections | |
650 | 2 | |a Diabetes Mellitus | |
650 | 2 | |a Diabetes Mellitus, Type 2 | |
650 | 4 | |a Medical Condition: Coronavirus Infection, Diabetes Mellitus, Type 2 | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a Phase: Phase 3 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 08. Sept. |
773 | 1 | 8 | |g year:2021 |g day:08 |g month:09 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04510493 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 08 |c 09 |